Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 4:6:38.
doi: 10.3389/fcell.2018.00038. eCollection 2018.

Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors

Affiliations
Review

Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors

Luca Cassetta et al. Front Cell Dev Biol. .

Abstract

Inhibition of immune checkpoint pathways in CD8+ T cell is a promising therapeutic strategy for the treatment of solid tumors that has shown significant anti-tumor effects and is now approved by the FDA to treat patients with melanoma and lung cancer. However the response to this therapy is limited to a certain fraction of patients and tumor types, for reasons still unknown. To ensure success of this treatment, CD8+ T cells, the main target of the checkpoint inhibitors, should exert full cytotoxicity against tumor cells. However recent studies show that tumor-associated macrophages (TAM) can impede this process by different mechanisms. In this mini-review we will summarize recent studies showing the effect of TAM targeting on immune checkpoint inhibitors efficacy. We will also discuss on the limitations of the current strategies as well on the future scientific challenges for the progress of the tumor immunology field.

Keywords: CD8+ T cell; TAM; checkpoint inhibitor; immunotherapy; macrophage; tumor immunology; tumor microenvironment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Potential therapeutic strategies to enhance immune checkpoint inhibitors by targeting tumor-associated macrophages (TAM). (A) Cytotoxicity of CD8+ T cell in the tumors is suppressed by immune checkpoint pathways activated by cancer cells and TAM. TAM also suppresses CD8+ T cell functions via checkpoint pathway independent mechanisms that are still under investigation. (B) Blockade of immune checkpoint pathway by antibodies for CTLA4, PD1, and PD-L1 enhances CD8+ T cell cytotoxicity. However, immune suppressive tumor microenvironment, especially TAM in it, will limit the anti-tumor efficacy of the checkpoint inhibitors. (C) Therapeutic efficacy of checkpoint inhibitors can be improved by TAM targeting through different strategies, i.e., TAM depletion (left), TAM reprogramming (central), and targeting functional molecules of TAM (right). MΦ means macrophage.

References

    1. Arlauckas S. P., Garris C. S., Kohler R. H., Kitaoka M., Cuccarese M. F., Yang K. S., et al. (2017). In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci. Transl. Med. 9:eaal3604 10.1126/scitranslmed.aal3604 - DOI - PMC - PubMed
    1. Brigati C., Noonan D. M., Albini A., Benelli R. (2002). Tumors and inflammatory infiltrates: friends or foes? Clin. Exp. Metastasis 19, 247–258. 10.1023/A:1015587423262 - DOI - PubMed
    1. Cannarile M. A., Weisser M., Jacob W., Jegg A. M., Ries C. H., Rüttinger D. (2017). Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer 5:53. 10.1186/s40425-017-0257-y - DOI - PMC - PubMed
    1. de Haas N., de Koning C., Spilgies L., de Vries I. J., Hato S. V. (2016). Improving cancer immunotherapy by targeting the STATe of MDSCs. Oncoimmunology 5:e1196312. 10.1080/2162402X.2016.1196312 - DOI - PMC - PubMed
    1. DeNardo D. G., Brennan D. J., Rexhepaj E., Ruffell B., Shiao S. L., Madden S. F., et al. . (2011). Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54–67. 10.1158/2159-8274.CD-10-0028 - DOI - PMC - PubMed